Clinical-stage biotech company Noxopharm (ASX:NOX) has completed the HERACLES clinical trial after finishing the second and final multiple-dose cohort of its SOF-SKN program, with no clinically relevant safety issues identified.
The Safety Steering Committee confirmed the treatment was safe and well tolerated across all dosing groups, marking the successful conclusion of the trial's clinical phase following rapid progression through recruitment, single-dose and multiple-dose cohorts, and high participant compliance.
On the back of the positive safety outcome, Noxopharm is preparing to commence Phase 2-enabling studies and drug scale-up, advancing development of SOF-SKN for cutaneous lupus erythematosus, with potential expansion into other autoimmune-related skin diseases.
At the time of reporting, Noxopharm's share price was $0.082.